Results 171 to 180 of about 39,262 (226)

MSC-Derived Apoptotic Vesicles Restore Bone Marrow Niche Homeostasis in Postmenopausal Osteoporosis by miRNA-Mediated Suppression of MAPK and NF-κB Signaling Nodes. [PDF]

Pharmaceuticals (Basel)
Tu Z, Wu H, Jiang Y, Li X, Huang Z, Shi S, Ren R.   +6 more
europepmc   +1 more source

Biomimetic hybrid nanocarriers hitchhike neutrophils for targeted ginsenoside Rc delivery to BMSCs: ameliorating postmenopausal osteoporosis via iron homeostasis regulation. [PDF]

J Nanobiotechnology
He Y, Fang D, Huang B, Chen X, Zhang Z, Wang Z, Jiang Q, Guo B, Xiao W.   +8 more
europepmc   +1 more source

Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III study. [PDF]

J Orthop Translat
Gu J, Chao A, Huo Y, Zhang Y, Yuan Z, Zhang J, Cheng Z, Mao L, Li Y, Xue Q, Liu F, Zeng Y, Zhu Y, Zhang M, Li L, Liu L, Gao F, Cheng Q, Jiang X, Wang C, Cheng J, Jin P, Xu C, Yang Y, Hua F, Cai H, Zhang Y, Xiong X, Hu J, Bai Y, Chen L, Li W, Zheng L, Deng Z, Song C, Tan L, Ding Y, Mu S, Liu J, Lian X, Zhao Q, Zhang Z.   +41 more
europepmc   +1 more source

Sijing Pill modulates PGE2/EP4/PI3K-AKT pathway via gut-bone axis to treat postmenopausal osteoporosis. [PDF]

Front Microbiol
Zhu X, Li Y, Meng X, Jiang T, Li C, Zhu X, Yin Z, Guo J, Su X.   +8 more
europepmc   +1 more source

LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis. [PDF]

J Endocr Soc
Krecipro-Nizinska E, Pluskiewicz W, Supronik J, Szeles P, Petit-Frere C, Varone E, Ferrari S, Valter I.   +7 more
europepmc   +1 more source

Cost-effectiveness analysis of Chinese patent medicines for the treatment of postmenopausal osteoporosis in China. [PDF]

Front Public Health
Wang C, Lin X, Liu J, Zhang Y, You R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Postmenopausal Osteoporosis

New England Journal of Medicine, 2023
Elizabeth Shane
exaly   +3 more sources

Treatment of Postmenopausal Osteoporosis

New England Journal of Medicine, 1998
Osteoporosis affects an estimated 75 million people in Europe, the United States, and Japan.1 It is a preventable and treatable condition, yet many people with osteoporosis remain unrecognized and untreated. The purpose of this review is to consider the evidence that treatments for postmenopausal osteoporosis are effective and safe.
Richard Eastell, Eastell Richard
exaly   +3 more sources

Treatment of postmenopausal osteoporosis

Lancet, The, 2002
The aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease. Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1-34 fragment of parathyroid hormone, and ...
exaly   +3 more sources

Postmenopausal Osteoporosis

Medical Clinics of North America, 1987
Osteoporosis is a major public health problem, particularly for the postmenopausal woman. With the withdrawal of estrogen at menopause, bone resorption begins to exceed formation in remodeling cycles and bone mass is inexorably lost. Clearly, preventing postmenopausal osteoporosis is the aim of management.
S J, Silverberg, R, Lindsay
openaire   +4 more sources